A Phase 3 interventional study of tenecteplase and alteplase in Stroke, sponsored by Boehringer Ingelheim. Completed at 55 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tenecteplase in Stroke — 10 open to participants now, 10 under way, 9 of them phase 3. Tenecteplase · Stroke.
Among the 28 studies testing tenecteplase in Stroke, this one is the 5th largest by enrollment, is one of 6 that started in 2021, is one of 15 in phase 3, and was the 15th registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →10 of the 28 studies testing tenecteplase in Stroke are open now, in 6 countries. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
ProMedica Health System · Sites in United States
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18+
University of Calgary · Sites in Australia, Canada
Ages 18+
The George Institute · Sites in Australia, Canada
Ages 18+
By country, each count listing its studies:
Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 18 · Phase 4 1
First in 2005; this study’s year is marked. 6 started in 2021.
This study's enrollment of 1,489 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 337 across the 28 interventional studies. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 28 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
23 studies in Stroke by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 23 studies in Stroke by Boehringer Ingelheim, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 3, and was the 20th registered.
Boehringer Ingelheim’s Stroke studies by the year they started, since 1998.
2 of the studies testing tenecteplase in Stroke that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing tenecteplase in Stroke, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 23 in Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30 minutes after stroke. The purpose of this study is to compare how tenecteplase and alteplase improve peoples' recovering of physical activity. Alteplase is standard of care. Tenecteplase is a modified variant of alteplase that is easier to administer and is approved to treat heart attack. This study is to find out whether tenecteplase is as good as alteplase in people with ischaemic stroke.
Participants are equally put into 2 treatment groups by chance. Participants in one group get tenecteplase as a single injection into a vein. Participants in the other group get alteplase as an injection into a vein (10% of the dose) and the remainder as an infusion over 1 hour.
Participants are in the study for about 3 months. They are in the hospital for the first week after treatment. Then they visit the study site 1 and 3 months after treatment. At these visits, peoples' ability to independently carry out daily activities is assessed. Scores for physical activity are compared between both treatment groups. The doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Acute bleeding diathesis, including but not limited to
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of tenecteplase, 0.25 mg/kg via intravenous (iv) bolus no later than 4.5 hours (h) after symptom onset. Visits on Day 1 consisted of two further visits (Visit 2b and Visit 2c) that were performed 1 h and 2 h after the start of the treatment. Visits 3 to 5 for continuous follow-up were performed on day 2, 8 and 30 after the start of the treatment. Treated patient performed a 90-day follow-up visit after the treatment to complete the study.
Drug: tenecteplase
Chinese patients with AIS were screened (visit 1) and randomised (visit 2a) when admitted. Patients received a single dose of alteplase, 0.9 mg/kg, 10% via intravenous (iv) bolus and the remaining 90% of the total dose administered as an iv infusion over 1 h no later than 4.5 hours (h) after symptom onset. Visits on Day 1 consisted of two further visits (Visit 2b and Visit 2c) that were performed 1 h and 2 h after the start of the treatment. Visits 3 to 5 for continuous follow-up were performed on day 2, 8 and 30 after the start of the treatment. Treated patient performed a 90-day follow-up visit after the treatment to complete the study.
Drug: alteplase
tenecteplase
alteplase
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
Time frame: At Day 90±7 days
Percentage of Participants With Major Neurological Improvement (National Institutes of Health Stroke Scale (NIHSS) Score of 0 or Improvement of at Least 4 Points Compared With Baseline
Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. indivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention. Mild strokes (NIHSS \< 6): High likelihood of good recovery and independence, Moderate strokes (NIHSS 6-15): Variable outcomes depending on timely intervention, Severe strokes (NIHSS \> 15): Lower likelihood of recovery without significant disability and higher risk of mortality. Percentages are rounded to the nearest digits.
Time frame: At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Percentage of participants with Modified Rankin Scale (mRS) score of 0-2 is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
Time frame: At Day 90
Change From Baseline of National Institutes of Health Stroke Scale (NIHSS) Score
Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. indivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention. Restricted maximum likelihood (REML) based MMRM approach used to compare change from baseline in NIHSS score at day 90. If patient misses visit, missing data will not be imputed. The mixed effect model will handle missing data based on a likelihood method under MAR assumption. Change in NIHSS score from baseline = overall mean + treatment + visit + baseline NIHSS + age + time to drug administration since onset of stroke symptoms + treatment by visit interaction + baseline NIHSS by visit interaction + random error.
Time frame: At baseline and at Day 90
Distribution of Modified Rankin Scale (mRS)
Distribution of Modified Rankin Scale (mRS) is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.
Time frame: At Day 90
Percentage of Participants With Barthel Index Score ≥95
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. Percentages are rounded to the nearest digits.
Time frame: up to 90 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH) Per European Cooperative Acute Stroke Study (ECASS) Ⅲ Definition During On-treatment Period
Percentage of participants with Symptomatic Intracerebral Haemorrhage (sICH) per European Cooperative Acute Stroke Study (ECASS) Ⅲ definition during on-treatment period is presented. Percentages are rounded to the nearest digits.
Time frame: Up to 7 days.
Percentage of Participants Who Died by Day 90
Percentage of participants who died by day 90 is presented. Percentages are rounded to the nearest digits.
Time frame: up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Percentage of participants with Modified Rankin Scale (mRS) score of 5 or 6 is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
Time frame: At Day 90
The main objective of this multi-centre, prospective, randomised, open label, blinded endpoint (PROBE), active-controlled parallel group phase III trial was to assess whether tenecteplase was non-inferior to alteplase in favourable outcome in Chinese patients with acute ischaemic stroke (AIS) who were eligible for intravenous (i.v.) thrombolysis within 4.5 h of symptom onset.
| Milestone | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Started | 744 | 745 |
| Treated | 733 | 735 |
| Completed | 671 | 675 |
| Not completed | 73 | 70 |
| Withdrew: Lost to follow-up | 20 | 10 |
| Withdrew: Withdrawal by subject | 12 | 5 |
| Withdrew: Death | 34 | 44 |
| Withdrew: Not treated | 3 | 6 |
| Withdrew: Investigator removed subject | 1 | 2 |
| Withdrew: Questionnaire result not evaluated | 1 | 0 |
| Withdrew: Refuse of hospital visit | 1 | 3 |
| Withdrew: Subject withdrew | 1 | 0 |
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1 | 72.7 | 70.3 |
Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. indivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention. Mild strokes (NIHSS \< 6): High likelihood of good recovery and independence, Moderate strokes (NIHSS 6-15): Variable outcomes depending on timely intervention, Severe strokes (NIHSS \> 15): Lower likelihood of recovery without significant disability and higher risk of mortality. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Major Neurological Improvement (National Institutes of Health Stroke Scale (NIHSS) Score of 0 or Improvement of at Least 4 Points Compared With Baseline | 48.0 | 45.0 |
Percentage of participants with Modified Rankin Scale (mRS) score of 0-2 is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2 | 80.9 | 79.9 |
Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. indivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention. Restricted maximum likelihood (REML) based MMRM approach used to compare change from baseline in NIHSS score at day 90. If patient misses visit, missing data will not be imputed. The mixed effect model will handle missing data based on a likelihood method under MAR assumption. Change in NIHSS score from baseline = overall mean + treatment + visit + baseline NIHSS + age + time to drug administration since onset of stroke symptoms + treatment by visit interaction + baseline NIHSS by visit interaction + random error.
| score on a scale | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Change From Baseline of National Institutes of Health Stroke Scale (NIHSS) Score | -3.47 ± 0.34 | -3.02 ± 0.34 |
Distribution of Modified Rankin Scale (mRS) is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| mRS score = 0 | 40.3 | 40.5 |
| mRS score = 1 | 30.1 | 28.2 |
| mRS score = 2 | 7.8 | 9.4 |
| mRS score = 3 | 6.7 | 5.5 |
| mRS score = 4 | 4.8 | 6.4 |
| mRS score = 5 | 1.9 | 1.6 |
| mRS score = 6 | 4.6 | 6.0 |
| missing | 3.8 | 2.3 |
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Barthel Index Score ≥95 | 75.7 | 73.9 |
Percentage of participants with Symptomatic Intracerebral Haemorrhage (sICH) per European Cooperative Acute Stroke Study (ECASS) Ⅲ definition during on-treatment period is presented. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH) Per European Cooperative Acute Stroke Study (ECASS) Ⅲ Definition During On-treatment Period | 1.2 | 1.2 |
Percentage of participants who died by day 90 is presented. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants Who Died by Day 90 | 4.6 | 5.8 |
Percentage of participants with Modified Rankin Scale (mRS) score of 5 or 6 is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90. Percentages are rounded to the nearest digits.
| Percentage of participants | Tenecteplase Treatment Group | Alteplase Active Control Group |
|---|---|---|
| Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6 | 6.8 | 7.8 |
Collected over AEs are reported for the on-treatment period from start of treatment until end of residual effect period, up to 7 days. All cause mortality was reported from start of treatment until death by any cause, up to 97 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alteplase Active Control Group | 44/736 (6%) | 115/736 (15.6%) | 347/736 (47.1%) |
| Tenecteplase Treatment Group | 34/732 (4.6%) | 116/732 (15.8%) | 334/732 (45.6%) |
| Event | Alteplase Active Control Group | Tenecteplase Treatment Group |
|---|---|---|
| Cerebral haemorrhageNervous system disorders | 21/736 | 25/732 |
| Cerebral infarctionNervous system disorders | 14/736 | 16/732 |
| Haemorrhagic transformation strokeNervous system disorders | 16/736 | 10/732 |
| Deep vein thrombosisVascular disorders | 13/736 | 8/732 |
| Cardiac failureCardiac disorders | 8/736 | 8/732 |
| Brain herniationInjury, poisoning and procedural complications | 8/736 | 7/732 |
| PneumoniaInfections and infestations | 7/736 | 7/732 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/736 | 7/732 |
| Haemorrhage intracranialNervous system disorders | 7/736 | 5/732 |
| Haemorrhagic cerebral infarctionNervous system disorders | 7/736 | 3/732 |
| Event | Alteplase Active Control Group | Tenecteplase Treatment Group |
|---|---|---|
| ConstipationGastrointestinal disorders | 123/736 | 131/732 |
| Gingival bleedingGastrointestinal disorders | 78/736 | 79/732 |
| HypokalaemiaMetabolism and nutrition disorders | 77/736 | 70/732 |
| PneumoniaInfections and infestations | 65/736 | 55/732 |
| Urinary tract infectionInfections and infestations | 49/736 | 44/732 |
| HyperhomocysteinaemiaMetabolism and nutrition disorders | 45/736 | 44/732 |
| PyrexiaGeneral disorders | 43/736 | 33/732 |
| HypoproteinaemiaMetabolism and nutrition disorders | 41/736 | 32/732 |
| AnaemiaBlood and lymphatic system disorders | 37/736 | 32/732 |
Full Analysis Set (FAS): This patient set included all randomised patients who received any dose of treatment. Treatment assignment was as randomised. This was the primary analysis set for presentation of efficacy according to the intention-to-treat principle.
| Age, Continuous(Years) | Tenecteplase Treatment Group | Alteplase Active Control Group | Total |
|---|---|---|---|
| Mean | 65.1 ± 11.1 | 65.0 ± 11.1 | 65.0 ± 11.1 |
| Sex: Female, Male(Participants) | Tenecteplase Treatment Group | Alteplase Active Control Group | Total |
|---|---|---|---|
| Female | 215 | 231 | 446 |
| Male | 517 | 502 | 1019 |
| Ethnicity (NIH/OMB)(Participants) | Tenecteplase Treatment Group | Alteplase Active Control Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 732 | 733 | 1465 |
| Unknown or Not Reported | 0 | 0 | 0 |
| National Institutes of Health Stroke Scale (NIHSS) class 1 at baseline(Participants) | Tenecteplase Treatment Group | Alteplase Active Control Group | Total |
|---|---|---|---|
| NIHSS total score <6 | 299 | 297 | 596 |
| NIHSS total score 6 - 15 | 390 | 393 | 783 |
| NIHSS total score >=15 | 43 | 43 | 86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Jun 2021 to primary completion in Oct 2023, 27 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 27 months is below that.
Counting every sponsor, half of 129 studies reached it within 44 months; a quarter within 27 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase